Cargando…

Bcl-xL acts as an inhibitor of IP(3)R channels, thereby antagonizing Ca(2+)-driven apoptosis

Anti-apoptotic Bcl-2-family members not only act at mitochondria but also at the endoplasmic reticulum, where they impact Ca(2+) dynamics by controlling IP(3) receptor (IP(3)R) function. Current models propose distinct roles for Bcl-2 vs. Bcl-xL, with Bcl-2 inhibiting IP(3)Rs and preventing pro-apop...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosa, Nicolas, Ivanova, Hristina, Wagner, Larry E., Kale, Justin, La Rovere, Rita, Welkenhuyzen, Kirsten, Louros, Nikolaos, Karamanou, Spyridoula, Shabardina, Victoria, Lemmens, Irma, Vandermarliere, Elien, Hamada, Kozo, Ando, Hideaki, Rousseau, Frederic, Schymkowitz, Joost, Tavernier, Jan, Mikoshiba, Katsuhiko, Economou, Anastassios, Andrews, David W., Parys, Jan B., Yule, David I., Bultynck, Geert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990011/
https://www.ncbi.nlm.nih.gov/pubmed/34750538
http://dx.doi.org/10.1038/s41418-021-00894-w
_version_ 1784683294999183360
author Rosa, Nicolas
Ivanova, Hristina
Wagner, Larry E.
Kale, Justin
La Rovere, Rita
Welkenhuyzen, Kirsten
Louros, Nikolaos
Karamanou, Spyridoula
Shabardina, Victoria
Lemmens, Irma
Vandermarliere, Elien
Hamada, Kozo
Ando, Hideaki
Rousseau, Frederic
Schymkowitz, Joost
Tavernier, Jan
Mikoshiba, Katsuhiko
Economou, Anastassios
Andrews, David W.
Parys, Jan B.
Yule, David I.
Bultynck, Geert
author_facet Rosa, Nicolas
Ivanova, Hristina
Wagner, Larry E.
Kale, Justin
La Rovere, Rita
Welkenhuyzen, Kirsten
Louros, Nikolaos
Karamanou, Spyridoula
Shabardina, Victoria
Lemmens, Irma
Vandermarliere, Elien
Hamada, Kozo
Ando, Hideaki
Rousseau, Frederic
Schymkowitz, Joost
Tavernier, Jan
Mikoshiba, Katsuhiko
Economou, Anastassios
Andrews, David W.
Parys, Jan B.
Yule, David I.
Bultynck, Geert
author_sort Rosa, Nicolas
collection PubMed
description Anti-apoptotic Bcl-2-family members not only act at mitochondria but also at the endoplasmic reticulum, where they impact Ca(2+) dynamics by controlling IP(3) receptor (IP(3)R) function. Current models propose distinct roles for Bcl-2 vs. Bcl-xL, with Bcl-2 inhibiting IP(3)Rs and preventing pro-apoptotic Ca(2+) release and Bcl-xL sensitizing IP(3)Rs to low [IP(3)] and promoting pro-survival Ca(2+) oscillations. We here demonstrate that Bcl-xL too inhibits IP(3)R-mediated Ca(2+) release by interacting with the same IP(3)R regions as Bcl-2. Via in silico superposition, we previously found that the residue K87 of Bcl-xL spatially resembled K17 of Bcl-2, a residue critical for Bcl-2’s IP(3)R-inhibitory properties. Mutagenesis of K87 in Bcl-xL impaired its binding to IP(3)R and abrogated Bcl-xL’s inhibitory effect on IP(3)Rs. Single-channel recordings demonstrate that purified Bcl-xL, but not Bcl-xL(K87D), suppressed IP(3)R single-channel openings stimulated by sub-maximal and threshold [IP(3)]. Moreover, we demonstrate that Bcl-xL-mediated inhibition of IP(3)Rs contributes to its anti-apoptotic properties against Ca(2+)-driven apoptosis. Staurosporine (STS) elicits long-lasting Ca(2+) elevations in wild-type but not in IP(3)R-knockout HeLa cells, sensitizing the former to STS treatment. Overexpression of Bcl-xL in wild-type HeLa cells suppressed STS-induced Ca(2+) signals and cell death, while Bcl-xL(K87D) was much less effective in doing so. In the absence of IP(3)Rs, Bcl-xL and Bcl-xL(K87D) were equally effective in suppressing STS-induced cell death. Finally, we demonstrate that endogenous Bcl-xL also suppress IP(3)R activity in MDA-MB-231 breast cancer cells, whereby Bcl-xL knockdown augmented IP(3)R-mediated Ca(2+) release and increased the sensitivity towards STS, without altering the ER Ca(2+) content. Hence, this study challenges the current paradigm of divergent functions for Bcl-2 and Bcl-xL in Ca(2+)-signaling modulation and reveals that, similarly to Bcl-2, Bcl-xL inhibits IP(3)R-mediated Ca(2+) release and IP(3)R-driven cell death. Our work further underpins that IP(3)R inhibition is an integral part of Bcl-xL’s anti-apoptotic function.
format Online
Article
Text
id pubmed-8990011
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89900112022-04-22 Bcl-xL acts as an inhibitor of IP(3)R channels, thereby antagonizing Ca(2+)-driven apoptosis Rosa, Nicolas Ivanova, Hristina Wagner, Larry E. Kale, Justin La Rovere, Rita Welkenhuyzen, Kirsten Louros, Nikolaos Karamanou, Spyridoula Shabardina, Victoria Lemmens, Irma Vandermarliere, Elien Hamada, Kozo Ando, Hideaki Rousseau, Frederic Schymkowitz, Joost Tavernier, Jan Mikoshiba, Katsuhiko Economou, Anastassios Andrews, David W. Parys, Jan B. Yule, David I. Bultynck, Geert Cell Death Differ Article Anti-apoptotic Bcl-2-family members not only act at mitochondria but also at the endoplasmic reticulum, where they impact Ca(2+) dynamics by controlling IP(3) receptor (IP(3)R) function. Current models propose distinct roles for Bcl-2 vs. Bcl-xL, with Bcl-2 inhibiting IP(3)Rs and preventing pro-apoptotic Ca(2+) release and Bcl-xL sensitizing IP(3)Rs to low [IP(3)] and promoting pro-survival Ca(2+) oscillations. We here demonstrate that Bcl-xL too inhibits IP(3)R-mediated Ca(2+) release by interacting with the same IP(3)R regions as Bcl-2. Via in silico superposition, we previously found that the residue K87 of Bcl-xL spatially resembled K17 of Bcl-2, a residue critical for Bcl-2’s IP(3)R-inhibitory properties. Mutagenesis of K87 in Bcl-xL impaired its binding to IP(3)R and abrogated Bcl-xL’s inhibitory effect on IP(3)Rs. Single-channel recordings demonstrate that purified Bcl-xL, but not Bcl-xL(K87D), suppressed IP(3)R single-channel openings stimulated by sub-maximal and threshold [IP(3)]. Moreover, we demonstrate that Bcl-xL-mediated inhibition of IP(3)Rs contributes to its anti-apoptotic properties against Ca(2+)-driven apoptosis. Staurosporine (STS) elicits long-lasting Ca(2+) elevations in wild-type but not in IP(3)R-knockout HeLa cells, sensitizing the former to STS treatment. Overexpression of Bcl-xL in wild-type HeLa cells suppressed STS-induced Ca(2+) signals and cell death, while Bcl-xL(K87D) was much less effective in doing so. In the absence of IP(3)Rs, Bcl-xL and Bcl-xL(K87D) were equally effective in suppressing STS-induced cell death. Finally, we demonstrate that endogenous Bcl-xL also suppress IP(3)R activity in MDA-MB-231 breast cancer cells, whereby Bcl-xL knockdown augmented IP(3)R-mediated Ca(2+) release and increased the sensitivity towards STS, without altering the ER Ca(2+) content. Hence, this study challenges the current paradigm of divergent functions for Bcl-2 and Bcl-xL in Ca(2+)-signaling modulation and reveals that, similarly to Bcl-2, Bcl-xL inhibits IP(3)R-mediated Ca(2+) release and IP(3)R-driven cell death. Our work further underpins that IP(3)R inhibition is an integral part of Bcl-xL’s anti-apoptotic function. Nature Publishing Group UK 2021-11-08 2022-04 /pmc/articles/PMC8990011/ /pubmed/34750538 http://dx.doi.org/10.1038/s41418-021-00894-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Rosa, Nicolas
Ivanova, Hristina
Wagner, Larry E.
Kale, Justin
La Rovere, Rita
Welkenhuyzen, Kirsten
Louros, Nikolaos
Karamanou, Spyridoula
Shabardina, Victoria
Lemmens, Irma
Vandermarliere, Elien
Hamada, Kozo
Ando, Hideaki
Rousseau, Frederic
Schymkowitz, Joost
Tavernier, Jan
Mikoshiba, Katsuhiko
Economou, Anastassios
Andrews, David W.
Parys, Jan B.
Yule, David I.
Bultynck, Geert
Bcl-xL acts as an inhibitor of IP(3)R channels, thereby antagonizing Ca(2+)-driven apoptosis
title Bcl-xL acts as an inhibitor of IP(3)R channels, thereby antagonizing Ca(2+)-driven apoptosis
title_full Bcl-xL acts as an inhibitor of IP(3)R channels, thereby antagonizing Ca(2+)-driven apoptosis
title_fullStr Bcl-xL acts as an inhibitor of IP(3)R channels, thereby antagonizing Ca(2+)-driven apoptosis
title_full_unstemmed Bcl-xL acts as an inhibitor of IP(3)R channels, thereby antagonizing Ca(2+)-driven apoptosis
title_short Bcl-xL acts as an inhibitor of IP(3)R channels, thereby antagonizing Ca(2+)-driven apoptosis
title_sort bcl-xl acts as an inhibitor of ip(3)r channels, thereby antagonizing ca(2+)-driven apoptosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990011/
https://www.ncbi.nlm.nih.gov/pubmed/34750538
http://dx.doi.org/10.1038/s41418-021-00894-w
work_keys_str_mv AT rosanicolas bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT ivanovahristina bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT wagnerlarrye bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT kalejustin bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT larovererita bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT welkenhuyzenkirsten bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT lourosnikolaos bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT karamanouspyridoula bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT shabardinavictoria bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT lemmensirma bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT vandermarliereelien bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT hamadakozo bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT andohideaki bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT rousseaufrederic bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT schymkowitzjoost bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT tavernierjan bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT mikoshibakatsuhiko bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT economouanastassios bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT andrewsdavidw bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT parysjanb bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT yuledavidi bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis
AT bultynckgeert bclxlactsasaninhibitorofip3rchannelstherebyantagonizingca2drivenapoptosis